Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

NATerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
AnemiaFatigueUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Weekly procrit dosing

The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.

DRUG

Interval Dosing

The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.

Trial Locations (1)

97239-3098

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT00258440 - Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer | Biotech Hunter | Biotech Hunter